TSI was established in Cambridge, Mass. in 2006 as Thrombolytic Science International (TSI). A privately held vascular medicine and biotechnology company, TSI was founded upon discoveries made in the Vascular Research Laboratory at Beth Israel Deaconess Medical Center.
TSI is leading development of a next-generation therapy for ischemic stroke and myocardial infarction (MI, heart attack). The company’s vision is to bring clot-busting therapy directly to patients very soon after suffering an event, rather than patients having to wait to get to a hospital. This approach can save precious time and resources, but more importantly, should save lives and decrease the number and severity of often lifelong, debilitating side effects.
TSI’s novel treatment regimen, entering Phase II studies in 2018 and 2019, is based upon pioneering work of Harvard researcher and TSI Co-founder Victor Gurewich, MD, on prourokinase (proUK) – a compound that has been proven effective in 27 clinical studies.
TSI controls several granted patent families and patent filings in the U.S., Europe, China and the rest of the world, including, but not limited to, the treatment of stroke. TSI also controls other exclusively licensed rights from Beth Israel Deaconess Medical Center in Boston, MA.